Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank cut its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 92.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,440 shares of the company's stock after selling 343,899 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Ionis Pharmaceuticals were worth $1,489,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. SG Americas Securities LLC raised its holdings in shares of Ionis Pharmaceuticals by 113.3% during the 3rd quarter. SG Americas Securities LLC now owns 41,571 shares of the company's stock worth $1,886,000 after acquiring an additional 22,078 shares in the last quarter. Commonwealth Equity Services LLC raised its holdings in shares of Ionis Pharmaceuticals by 4.4% during the 3rd quarter. Commonwealth Equity Services LLC now owns 21,470 shares of the company's stock worth $974,000 after acquiring an additional 897 shares in the last quarter. Raymond James & Associates raised its holdings in shares of Ionis Pharmaceuticals by 1.4% during the 3rd quarter. Raymond James & Associates now owns 194,629 shares of the company's stock worth $8,828,000 after acquiring an additional 2,745 shares in the last quarter. NBT Bank N A NY purchased a new stake in Ionis Pharmaceuticals during the 3rd quarter valued at $773,000. Finally, TD Asset Management Inc raised its holdings in Ionis Pharmaceuticals by 14.5% during the 3rd quarter. TD Asset Management Inc now owns 898,852 shares of the company's stock valued at $40,772,000 after buying an additional 113,644 shares during the period. 93.86% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Eric Swayze sold 1,907 shares of the stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $49.56, for a total value of $94,510.92. Following the completion of the sale, the executive vice president now directly owns 34,324 shares in the company, valued at $1,701,097.44. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Ionis Pharmaceuticals news, EVP Eric Swayze sold 1,907 shares of the stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $49.56, for a total value of $94,510.92. Following the completion of the sale, the executive vice president now directly owns 34,324 shares in the company, valued at $1,701,097.44. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Joseph Baroldi sold 4,006 shares of the stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $41.60, for a total value of $166,649.60. Following the completion of the sale, the executive vice president now owns 19,631 shares of the company's stock, valued at $816,649.60. The disclosure for this sale can be found here. Insiders have sold a total of 42,699 shares of company stock valued at $2,104,091 over the last quarter. 2.65% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

IONS has been the topic of several recent research reports. Royal Bank of Canada increased their price target on Ionis Pharmaceuticals from $65.00 to $70.00 and gave the company an "outperform" rating in a report on Friday, January 26th. Piper Sandler increased their price target on Ionis Pharmaceuticals from $62.00 to $63.00 and gave the company an "overweight" rating in a report on Thursday, February 22nd. William Blair restated an "outperform" rating on shares of Ionis Pharmaceuticals in a report on Tuesday, April 9th. Oppenheimer increased their price target on Ionis Pharmaceuticals from $72.00 to $75.00 and gave the company an "outperform" rating in a report on Tuesday, April 9th. Finally, JPMorgan Chase & Co. increased their price target on Ionis Pharmaceuticals from $52.00 to $55.00 and gave the company a "neutral" rating in a report on Thursday, February 1st. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Ionis Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $56.08.

Ionis Pharmaceuticals Stock Down 0.6 %

Shares of IONS traded down $0.25 during midday trading on Friday, reaching $41.59. 556,043 shares of the stock were exchanged, compared to its average volume of 1,129,417. Ionis Pharmaceuticals, Inc. has a 52 week low of $34.32 and a 52 week high of $54.44. The company has a current ratio of 5.90, a quick ratio of 5.83 and a debt-to-equity ratio of 3.18. The company's 50 day moving average is $43.33 and its two-hundred day moving average is $47.19. The company has a market capitalization of $6.06 billion, a P/E ratio of -16.26 and a beta of 0.39.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last issued its quarterly earnings data on Wednesday, February 21st. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.78) by $0.72. Ionis Pharmaceuticals had a negative return on equity of 90.29% and a negative net margin of 46.32%. The company had revenue of $325.00 million for the quarter, compared to the consensus estimate of $176.01 million. During the same quarter last year, the company earned ($0.37) earnings per share. The firm's revenue for the quarter was up 113.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Ionis Pharmaceuticals, Inc. will post -3.88 earnings per share for the current year.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.